Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stellate Ganglion Block for COVID-19-Induced Parosmia
NCT06253806Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mepivacaine in parosmia (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Parosmia Olfactory Dysfunction Outcomes Rating at 3 months. Started Oct 2023; status: completed.
02
Drugs
mepivacaine
03
Conditions
parosmia
Beyond the preview
Go deeper on NCT06253806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06253806.